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■ Abstract
Objective: We conducted a large observational study in 193 children and adolescents with allergic rhinitis due to grass or tree pollens to 
evaluate the safety and tolerability of an ultrarush high-dose sublingual immunotherapy (SLIT) regimen reaching a maintenance dose of 
300 index of reactivity within 90 minutes.
Methods: Children and adolescents aged 5 to 17 years with at least a 1-year medical history of allergic rhinitis with or without mild 
to moderate asthma due to tree pollens (birch, alder, hazel) or grass pollens (cocksfoot, meadow grass, rye grass, sweet vernal grass, 
timothy) were recruited. Standardized grass and tree pollen allergen extracts were used for ultrarush titration and subsequent coseasonal 
maintenance.
Results: During ultrarush titration, 60 patients (31%) reported 117 predominantly mild and local adverse events, which resolved within 
150 minutes. During the maintenance phase, 562 adverse events were reported; the most frequent local events were oral pruritus, burning 
sensation, lip or tongue swelling, and gastrointestinal symptoms, and the most frequent systemic events were rhinoconjunctivitis and 
asthma. There was 1 clinically signifi cant asthma event in an 11-year old boy with known asthma in whom SLIT was resumed after an 
interval of 4 days.
Conclusion: Ultrarush titration was safe and well tolerated. Pediatric patients with asthma should be carefully monitored and adequately 
trained to use their rescue medications.
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■ Resumen
Objetivos: Realizamos un gran estudio observacional con 193 niños y adolescentes con rinitis alérgica debido a gramíneas y pólenes de 
árboles para evaluar la seguridad y tolerancia de un régimen de inmunoterapia sublingual ultrarrápida a dosis alta  (ITSL) alcanzando la 
dosis de mantenimiento de 300 índice de reactividad en 90 minutos. 
Métodos: Se reclutaron niños y adolescentes entre 5 y 17 años con al menos 1 año de historia clínica de rinitis alérgica con o sin asma 
leve a moderado debido a pólenes de árboles (abedul, aliso, avellano) o gramíneas (dáctilo, poa común, lolium, grama de olor, hierba 
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timotea). Se emplearon extractos estandarizados de gramíneas, y de pólenes de árboles para la pauta ultra-rápida y la posterior dosis de 
mantenimiento coestacional. 
Resultados: Durante la pauta ultra-rápida, 60 pacientes (31%) presentaron 117 reacciones adversas predominantemente leves y locales, 
que se resolvieron en 150 minutos. Durante la fase de mantenimiento, se notifi caron 562  reacciones adversas; las más frecuentes fueron 
el prurito oral, sensación de ardor, infl amación de labios o lengua, y síntomas gastrointestinales, y las  reacciones sistémicas más frecuentes 
fueron rinoconjuntivitis y el asma.  Una reacción clínicamente signifi cativa de asma ocurrió en un niño de 11 años de edad con asma 
conocida en el que la ITSL fue reiniciada tras un intervalo de 4 días. 
Conclusión: La pauta ultra-rápida fue segura y bien tolerada. Los pacientes pediátricos con asma deberían monitorizarse cuidadosamente 
y ser entrenados adecuadamente para emplear su medicación de rescate.  
Palabras clave: Gramíneas. Árboles. Ultra rápida. Inmunoterapia sublingual. Niños. Seguridad. Rinitis alérgica. Asma. 
Introduction
Subcutaneous immunotherapy (SCIT) in allergic rhinitis 
has been linked to reduced development of later asthma and 
fewer symptoms in patients who already have asthma. [1,2]. The 
recommendation to use sublingual-swallow immunotherapy 
(SLIT) in children and adults with allergic rhinitis evolved over 
several years based on the following key publications: a) the 
World Health Organization (WHO) position paper on allergen 
immunotherapy [3], b) the Allergic Rhinitis and its Impact 
on Asthma (ARIA) Workshop Report in collaboration with 
the WHO (2001) [1] and its 2008 update [2], c) the Cochrane 
review of SLIT for allergic rhinitis based on 22 studies 
involving 979 children and adults [4], and d) a meta-analysis 
evaluating the effi cacy of SLIT in the treatment of allergic 
rhinitis in children and adolescents aged 3 to 18 years [5]. 
Subcutaneous immunotherapy (SCIT), in contrast, while 
effective in children and adults, is burdened by the risk of side 
effects, which at times may be life threatening [2]. 
Allergen doses in SLIT have increased considerably 
over the past 10 years and are now up 500 times greater than 
those commonly administered with SCIT. A meta-analysis 
published in 2005 showed that the frequency of adverse 
events associated with SLIT was not dose dependent [6]. 
In the analysis, 25 controlled studies on SLIT were divided 
into 2 groups: 1 using low allergen doses (≤50 times the dose 
commonly administered with SCIT) (13 studies) and another 
with high allergen doses (> 50 times the dose used with SCIT) 
(12 studies). While local side effects were observed more 
frequently in the low-dose group (P < .0001), there was no 
signifi cant difference in the occurrence of systemic reactions. 
SLIT dosing regimens traditionally consisted of an induction 
phase lasting a couple of weeks followed by a maintenance 
phase lasting months or years. In 1995, a rush preseasonal 
treatment schedule designed to reach the maintenance dose in 
15 days with twice-daily administrations in 34 adult patients 
with grass pollen–induced allergic rhinoconjunctivitis was 
shown to be safe and well tolerated [7]. A similar schedule 
(designed to reach the maintenance dose in 18 days with 
twice-daily administrations) in 30 adult patients with tree 
pollen–induced allergic rhinoconjunctivitis showed similar 
results [8]. More recently, an ultrarush high-dose SLIT regimen 
that reached a maintenance dose of 300 index of reactivity 
(IR) with Juniperus ashei allergen extract within 90 minutes 
(30–90–150–300 IR) proved to be safe in adult patients [9]; 
only local adverse events such as mouth and tongue itching 
were observed in both the SLIT group and the placebo group 
during the ultrarush titration phase.
In children, ultrarush high-dose SLIT regimens have 
been evaluated in 2 studies to date. In the fi rst, a group of 28 
children with allergic rhinitis (n = 18) or asthma (n = 10) due 
to grass or Parietaria pollens or house dust mites received 
ultrarush high-dose SLIT using a chemically modifi ed allergen 
extract (monomeric allergoids) [10]. The patients (28 children 
and 77 adults) received doses of 100-300-600-1000-2000 
allergenic units every 5 minutes. All the patients tolerated 
the treatment very well. In the second study, 100 children 
received ultrarush high-dose SLIT using allergen extracts 
from 2 different manufacturers; the extracts were grass pollens 
(43%), house dust mites (44%), Parietaria (9%), olive (3%), 
and Alternaria (1%) [11]. The ultrarush regimen used for one 
of the allergen extracts (Staloral) was 30–60–120–180–240 IR 
every 10 minutes. Thirteen (42%) of the patients (31 children 
and adolescents aged 6-17 y) experienced mild local adverse 
events. No severe events were observed.
We conducted a large observational study in 193 children 
and adolescents with allergic rhinitis due to grass or tree 
pollens to evaluate the safety and tolerability of an ultrarush 
high-dose SLIT regimen reaching a maintenance dose of 300 
IR within 90 minutes (30-90-150-300 IR). The subsequent 
maintenance phase at 300 IR (once-daily dose) lasted up to 4 
months, depending on the length of the pollen season.
Material and Methods
Patients and Study Design
Children and adolescents aged 5 to 17 years with at least 
a 1-year history of allergic rhinitis with or without mild to 
moderate asthma due to grass pollens (cocksfoot, meadow 
grass, rye grass, sweet vernal grass, timothy) or tree pollens 
(birch, alder, hazel) were recruited at 13 study centers (9 in 
Germany and 4 in Italy) between January and July 2004. 
Positive skin prick tests to tree or grass pollens were required. 
Patients fulfi lling any of the following criteria were excluded: 
immunotherapy in the past 3 years, absolute or relative 
contraindications to immunotherapy, and the presence of a 
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condition which could compromise the patient’s safety during 
the study. Written informed consent was obtained from children 
and their parents or caregivers. The study was approved by 
the ethics committee at the Lower Saxony Medical Council 
and the competent authority (Paul Ehrlich Institute, Langen, 
Germany).
Standardized mixtures of grass pollen (cocksfoot, meadow 
grass, rye grass, sweet vernal grass, and timothy) and tree 
pollen (birch, alder, and hazel) allergen extracts in aqueous 
solution were used for SLIT (Staloral; Stallergènes, Antony, 
France). The biological activity of the extracts was assessed 
in comparison with an internal standard in vitro and in vivo, 
and expressed as IR [12].
An ultrarush titration high-dose SLIT regimen reaching a 
maintenance dose of 300 IR within 90 minutes (30–90–150–
300 IR) was used. During the titration phase, just before the 
next dose and 60 minutes after the most recent dose, patients 
were asked if they had experienced any adverse events and 
were also physically examined for the presence of local or 
systemic reactions. Forced expiratory volume in 1 second was 
measured in patients with asthma before titration. In addition, 
3 consecutive peak fl ow rate (PFR) measurements (standing) 
were performed before each titration step. Following titration, 
patients received a once-daily maintenance dose of 300 IR 
for up to 4 months if they had reached this dose level during 
the titration phase. In most cases, SLIT was initiated after 
the beginning of the pollen season (coseasonal treatment for 
specifi c allergens).
During the maintenance period, safety was evaluated using 
patient diary cards on which patients and/or their parents 
were asked to report any adverse events. If an adverse event 
occurred, patients and/or their parents were required to inform 
the investigator before modifying the dose. At the end of the 
ultrarush titration phase, investigators and patients performed a 
Recruited
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Titration of
study drug
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No diaries
n = 9
Patient diaries available
(maintenance phase)
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Figure 1. Study fl ow charts showing patient numbers.
global assessment of tolerability using a visual analogue scale 
(VAS) ranging from 0 (poor) to 100 (very good).
The following symptomatic drugs were allowed to treat 
allergic reactions caused by pollen exposure or SLIT during 
titration and maintenance phases: oral loratadine or cetirizine, 
ocular and nasal azelastine, oral and rectal corticosteroids 
such as prednisolone, nasal fl uticasone, corticosteroids for 
inhalation, selective ß
2
-adrenoceptor agonists for inhalation, 
and, in case of emergency, adrenaline (self-injection kit).
Statistical Analysis
The primary endpoint was the frequency and intensity 
(mild, moderate, or severe) of expected local, gastrointestinal, 
and generalized adverse events. The secondary endpoint was 
the global assessment of tolerability by investigators and 
patients.
Adverse events were presented descriptively, along with 
intensity, relationship to study medication, action taken, and 
outcome. A serious adverse event was defi ned as any untoward 
event which resulted in death or persistent or signifi cant 
disability or incapacity, required in-patient hospitalization or 
prolongation of existing hospitalization, or was life threatening 
or medically signifi cant. Systemic reactions were graded 
according to guidelines published by the European Academy 
of Allergology and Clinical Immunology (EAACI) [13].
Most parameters were available as ordinal data. For these 
parameters, frequency counts and percentages were provided 
and presented graphically where appropriate. Score means 
were also calculated for ordinal data where appropriate. 
Nominal data, including dichotomous data, were described 
by frequency counts and percentages. Interval data, including 
VAS readings, were characterized by mean, SD, minimum, and 
maximum values, and 95% confi dence limits of the mean.
The sample size selected for this observational study was 
based on previous experience of the frequency of adverse 
events during SLIT. With 100 patients, the power required to 
detect an adverse event in 1% of patients undergoing SLIT was 
found to be 84%, and the power to detect an adverse event in 
1.6% of the patients was 95%.
Results
A total of 193 children and adolescents, 66 girls (34%) and 
127 boys (66%), aged 5 to 17 years (mean age, 10.3 y), were 
enrolled in the study. Nearly all of the patients had allergic 
rhinitis (n = 182, 94%); 132 (68%) had concomitant allergic 
conjunctivitis and 110 (57%) had mild or moderate asthma. All 
of the patients were titrated to the 300 IR maintenance dose: 
84 patients with tree pollen extracts and 109 patients with 
grass pollen extracts. Concomitant medication specifi ed in the 
protocol was taken by most of the patients (n = 144, 75%).
During ultrarush titration, 60 patients (31%) reported a total 
of 117 adverse events, predominantly after the second dose (90 
IR) at the 30-minute time point. Nearly all of the adverse events 
(n = 85, 73%) were mild and local; they included oral pruritus, 
burning sensation, lip or tongue swelling, and gastrointestinal 
symptoms such as abdominal pain, gastroenteritis, and nausea 
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Table 1. Frequency and Severity of Adverse Events Observed During Ultrarush Titration 
   Mild  Moderate  Severe Total
Adverse Event 
 No. % No. % No. % No. %
Local adverse events
   Oral pruritus/burning sensation 72 61.5 7 6.0 0 0.0 79 67.5
   Lip/tongue swelling 9 7.7 3 2.6 0 0.0 12 10.3
   Gastrointestinal events 4 3.4 0 0.0 0 0.0 4 3.4
Systemic adverse events
   Rhinoconjunctivitis 11 9.4 1 0.9 0 0.0 12 10.3
   Asthma 0 0.0 0 0.0 0 0.0 0 0.0
   Urticaria, erythema, pruritus 9 7.7 0 0.0 0 0.0 9 7.7
   Nonspecifi c events (eg. tiredness) 1 0.9 0 0.0 0 0.0 1 0.9
   Other events 0 0.0 0 0.0 0 0.0 0 0.0
Total 106 90.6 11 9.4 0 0.0 117 100
(Table 1). Mild rhinoconjunctivitis and urticaria were the most 
frequent systemic adverse events (Table 1). No severe events 
were observed during ultrarush titration and all events resolved 
within 30 to 150 minutes. Virtually all of the adverse events 
were considered to be at least possibly related to SLIT by the 
investigators. 
The overall assessment of tolerability by the investigators 
and patients showed mean (SD) scores of 83.7 (13.7) and 85.9 
(12.6), respectively. As the maximum VAS score was 100, 
these results demonstrated a good to very good tolerability of 
ultrarush titration.
Pulmonary function during ultrarush titration remained 
within the normal range in all of the patients with asthma.
A total of 184 patients received the planned daily 
maintenance dose of 300 IR at the beginning of the 
maintenance phase and 133 of these completed the 4-month 
treatment period.
During the maintenance phase, 139 patients reported 562 
adverse events. The most frequently reported events were local 
events such as oral pruritus, burning sensation, lip or tongue 
Table 2. Frequency and Severity of Adverse Events Observed During the Maintenance Phase 
   Mild  Moderate  Severe Total
Adverse Event 
 No. % No. % No. % No. %
Local adverse events
   Oral pruritus/burning sensation 54 9.6 22 3.9 7 1.2 83 14.8
   Lip/tongue swelling 31 5.5 27 4.8 2 0.9 60 10.7
   Gastrointestinal events 20 3.6 8 1.4 1 0.2 29 5.2
Systemic adverse events
   Rhinoconjunctivitis 101 17.9 42 7.5 4 0.7 147 26.2
   Asthma 21 3.7 13 2.3 4 0.7 38 6.8
   Atopic dermatitis 2 0.4 3 0.5 0 0.0 5 0.9
   Nonspecifi c events (eg. tiredness) 8 1.4 4 0.7 4 0.7 16 2.8
   Other events 97 17.3 71 12.6 16 2.8 184 32.7
Total 334 59.4 190 33.8 38 6.8 562 100
swelling, and gastrointestinal symptoms (n = 172, 31%), and 
systemic events such as rhinoconjunctivitis (n = 147, 26%) 
and asthma (n = 38, 7%) (Table 2). Most adverse events were 
mild (n = 334, 60%) or moderate (n = 190, 34%). A total of 38 
(7%) severe adverse events were observed, predominantly 
application site-related events, rhinoconjunctivitis, and asthma 
(Table 2). Most adverse events (n = 397, 71%) were assessed 
as at least possibly related to SLIT by the investigators. The 
majority of events (n = 327, 58%) occurred during the fi rst 
month of the maintenance phase (Figure 2). Only a few 
events (n = 101, 18%) resulted in a reduced SLIT dose for the 
remainder of the maintenance phase, and virtually all of the 
events (n = 537, 94%) had resolved by the end-of-study visit.
Only 1 of the 4 severe asthma events (graded according to 
EAACI guidelines [13]) was considered clinically signifi cant 
(according to International Conference on Harmonization 
[ICH] guidelines [14] by the investigators). An 11-year old 
boy with a 4-year history of sensitization to birch, alder, 
hazel, grasses, and house dust mites for 4 years and a 2-year 
history of allergic asthma had normal PFR measurements at 
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Figure 2. Number of adverse events during ultra-rush titration and 4-month maintenance phase. AEs indicates adverse events.
the beginning of the study. He experienced only mild local 
adverse events during ultrarush titration with grass pollen 
extract but developed dysphagia and dyspnea on day 4 of 
the maintenance phase, immediately after the 300 IR dose. 
Following intravenous remedial treatment with 100 mg of 
prednisone, clemastine, and 150 mg of theophylline, the boy 
recovered. Subsequent treatment consisted of rectal prednisone 
and epinephrine for inhalation. After 4 days, SLIT was resumed 
with gradually increasing doses up to 300 IR.
Discussion
This large observational study of 193 children and 
adolescents demonstrated that an ultrarush high-dose SLIT 
regimen reaching a maintenance dose of 300 IR within 90 
minutes (30-90-150-300 IR) was safe and well tolerated. 
Similar results in adult patients using standardized Juniperus 
ashei allergen extracts from the same manufacturer have been 
previously reported [9]. Although ultrarush titration lasted only 
90 minutes, the incidence and intensity of adverse events in this 
study were comparable to those reported in pediatric studies 
using traditional titration regimens [15-17]. In a recently 
published study using a 40-minute ultrarush titration regimen, 
31 children and adolescents aged 6 to 17 years received allergen 
extracts from the same manufacturer used in this study [11]. 
A total of 13 patients (42%) experienced mild local adverse 
events and no severe events were observed. It is of note that, 
in contrast to most other studies, in which SLIT was started 
before the pollen season, we exposed most of the patients to 
coseasonal ultrarush titration.
During the maintenance phase, 1 clinically signifi cant 
severe asthma event was observed. The event resolved after 
adequate remedial treatment and SLIT was resumed after 4 
days. Overall, asthmatic exacerbations are rarely observed 
during SLIT. A rate of 1 in 498 patients was reported in a 
recent comprehensive review [18]. Rates reported in pediatric 
populations are comparable to ours [19-21] and in 1 case 
slightly higher [22]. Studies on SLIT in 65 and 126 younger 
children aged 3 to 7 and 3 to 5 years, respectively, did not 
detect any asthma events [23,24].
In conclusion, this ultrarush high-dose SLIT regimen was 
safe and well tolerated in children and adolescents aged 5 to 
17 years at the start of and during the pollen season. Adverse 
events during ultrarush titration were mild or moderate and 
within the expected range for SLIT. They resolved rapidly 
and did not require extended medical supervision. Caution 
is, however, advised in children with asthma, who should be 
carefully monitored and adequately trained to use their rescue 
medications.
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